Raymond James Financial
VKTX icon

Raymond James Financial’s Viking Therapeutics VKTX Stock Holding History

Raymond James Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31M Sell
794,660
-1,280,743
-62% -$41.4M 0.01% 1256
2026
Q1 		$114M Buy
2,075,403
+1,153,405
+125% +$37.1M 0.04% 467
2025
Q4 		$32.4M Sell
921,998
-32,274
-3% -$1.14M 0.01% 1109
2025
Q3 		$25.1M Buy
954,272
+131,994
+16% +$3.94M 0.01% 1260
2025
Q2 		$21.8M Buy
822,278
+174,887
+27% +$4.6M 0.01% 1310
2025
Q1 		$15.6M Buy
647,391
+28,922
+5% +$914K 0.01% 1495
2024
Q4 		$24.9M Buy
+618,469
New +$35.3M 0.01% 1157

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Raymond James Financial's VKTX Position: Q2 2026 in Review

Raymond James Financial reduced its Viking Therapeutics (VKTX) stake by 62% in Q2 2026, selling an estimated $41.4M and leaving 794,660 shares worth $31M. The position accounts for 0.01% of the portfolio, ranked #1256.

Raymond James Financial first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $114M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Raymond James Financial held 794,660 shares of Viking Therapeutics worth $31M as of Q2 2026.
  • Raymond James Financial sold 1,280,743 Viking Therapeutics shares in Q2 2026, an estimated $41.4M.
  • Viking Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1256 holding.
  • Raymond James Financial first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Viking Therapeutics position peaked at $114M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.